Presidio Partners


Presidio Partners is a San Francisco–based venture investment firm that emphasizes active portfolio management and company-building across information technology, life sciences, and energy technology. The firm leverages 25+ years of venture and operating experience (formerly as CMEA Capital), a data-and-technology orientation, and practices intended to increase transparency and accountability (for example, assigning two Presidio team members to each major investment).

Industries

finance
venture-capital-b37d

Nr. of Employees

small (1-50)

Presidio Partners

2181 Greenwich Street San Francisco, CA 94123


Portfolio

Press items on product launches, patents, and a $33M Series D funding round noted on Presidio site.

#Life Sciences / Agricultural biotechnology

Noted on the site: completion of acquisition of Spitfire Pharma and development milestone toward a single-dose intranasal COVID-19 vaccine.

#Biotechnology / Vaccines

Press items reference executive team announcements and capital raises ($23M and $40M funding rounds reported in news items).

#Energy technology / Solar

A123 Systems completed a $5M equity investment (Series B) and Wildcat later raised over $20M in Series C financing according to Presidio content.

#Energy technology / Advanced materials for batteries

News items reference FDA approval and IPO-related events.

#Life Sciences / Pharmaceuticals

Multiple news items reference Series C financing, loan facility, patent issuance, and FDA approvals for products.

#Pharmaceuticals

View All Portfolio Items

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.